Related Experiment Video

Updated: Apr 14, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.5K

A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid

A Julià1, A Fernandez-Nebro2, F Blanco3

  • 1Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain.

The Pharmacogenomics Journal
|April 22, 2015
PubMed

Insights

Genetic variations in the MED15 gene influence rheumatoid arthritis treatment response to etanercept, a biologic agent. This genome-wide association study identifies potential new mechanisms for anti-tumor necrosis factor therapies.

Area of Science:

  • Genetics
  • Rheumatology
  • Pharmacogenomics

Background:

  • Biologic agents, specifically anti-Tumor Necrosis Factor (anti-TNF) drugs, are standard treatments for rheumatoid arthritis (RA).
  • A significant portion of RA patients (approximately 25%) do not respond adequately to anti-TNF therapy, necessitating research into predictive factors.
  • Understanding the genetic basis of treatment response can personalize therapy and improve patient outcomes.

Purpose of the Study:

  • To conduct a Genome-Wide Association Study (GWAS) to identify genetic variations associated with response to anti-TNF therapy in rheumatoid arthritis patients.
  • To discover novel genetic markers that predict efficacy of anti-TNF agents like etanercept, infliximab, and adalimumab.

Main Methods:

  • A GWAS was performed on 372 RA patients treated with anti-TNF agents, with treatment response assessed at 12 weeks.
  • A replication study using an independent cohort of 245 RA patients was conducted to validate significant findings from the discovery stage.
  • Statistical analysis focused on identifying genome-wide significant associations with treatment response.

Main Results:

  • A genome-wide significant association was identified in the MED15 gene with response to etanercept (P<1.5e-8).
  • The association at the MED15 locus was successfully replicated in an independent cohort.
  • Suggestive evidence of association was also found at the MAFB locus.

Conclusions:

  • Genetic variations, particularly within the MED15 gene, play a role in predicting response to etanercept therapy in rheumatoid arthritis.
  • These findings suggest novel biological mechanisms underlying anti-TNF therapy response and have implications for personalized medicine in RA.
  • Further research into the identified genetic loci may lead to improved patient stratification and treatment strategies.

More Related Videos

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

6.6K
Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

2.2K

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
804
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
94
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.1K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.5K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
70